Revolutionary Cancer Testing Technique Expands Across English Hospitals

A innovative cancer testing technique has been approved for broad deployment across NHS hospitals, expected to improve patient outcomes and broaden access to vital genetic analysis. Whole Genome Sequencing (WGS), which determines the nature and origins of cancers by examining a patient’s DNA, is now being rolled out across the East of England following a novel stabilisation technique developed at Addenbrooke’s Hospital in Cambridge. The innovation allows biological specimens to be maintained in a dedicated preservation medium and transported at room temperature, eliminating the former need for expensive minus 80 degrees Celsius cryogenic storage. The expansion, launched at the end of 2025, enables hospitals such as Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital to make available the test to more patients, potentially preventing avoidable surgical intervention and improving treatment outcomes across the region.

A Patient’s Path to Understanding

Laraine Chung’s situation demonstrates how WGS can transform a patient’s medical trajectory. The 63-year-old carer from Peterborough learned she had a tumour behind her left eye last year, but early investigations proved inconclusive about its character. Looking at the likelihood of complex surgery that could threaten her eyesight and possibly impact her brain and facial structures, Chung felt the strain of an uncertain future. However, her receipt of Whole Genome Sequencing at Addenbrooke’s Hospital delivered the breakthrough her clinical team urgently required to chart a safer course forward.

The genetic analysis revealed that Chung’s tumour was a benign form of meningioma, a diagnosis that substantially transformed her treatment plan. Rather than having extensive invasive surgery with prolonged recovery, she needed a far less complex procedure. “Without the test, I would have undergone significantly more complex surgery, and it would have involved even longer to recover,” Chung reflected. The grandmother-of-four described the moment she got her results as a deep sense of relief for both herself and her family, knowing that her vision could be protected and her ordeal substantially cut short.

The Research Behind the Advancement

Whole Genome Sequencing marks a major breakthrough in cancer diagnostics, providing clinicians an unprecedented window into the genetic architecture of cancerous and non-cancerous growths alike. By decoding the complete DNA blueprint of a patient’s cancer cells, WGS enables medical teams to establish not merely what type of cancer is present, but crucially, what specific genetic mutations are driving its growth. This granular understanding allows oncologists to tailor treatment strategies with remarkable precision, guiding patients away from unnecessary procedures and towards treatments with the highest success rates. The technology has already shown considerable benefit across the NHS, yet accessibility remained constrained by practical obstacles that the new storage method now resolves.

How Full Genome Sequencing Works

When a tissue sample is obtained from a patient, it contains invaluable genetic information that can inform treatment decisions. However, the genetic material within these samples deteriorates quickly, typically within hours, unless actively preserved. Traditionally, laboratories have frozen samples at minus 80 degrees Celsius, a process demanding specialised equipment and transport infrastructure unavailable at many hospital sites. The innovative preservation solution now used throughout the East of England stabilises the genetic material through chemical means, enabling secure transportation at room temperature and dramatically expanding access to this life-changing diagnostic capability.

• Determines specific cancer types and hereditary alterations fuelling cancer development
• Enables personalised treatment choice based on individual genetic profiles
• Uncovers origins of malignancies of unknown origin for precision treatment
• Guides clinicians away from unnecessary invasive surgical interventions

Reducing Logistical Obstacles to Treatment

For years, the most significant obstacle to expanding Whole Genome Sequencing across the NHS has not been scientific capability, but rather the practical challenges of moving fragile biological samples to local testing centres. Many hospitals, particularly those in rural and isolated locations, lack the specialist cold storage facilities necessary to protect genetic material during passage to centres like Cambridge University Hospitals NHS Foundation Trust. This capacity shortfall has effectively created a two-level structure, where patients at well-resourced academic hospitals obtain cutting-edge diagnostics whilst those at smaller community hospitals remain unable to access the same vital diagnostic technology. The new preservation technique effectively tackles this disparity.

The rollout across the East of England, beginning in late 2025, constitutes a significant milestone in democratising availability of cutting-edge cancer diagnostic services. Hospitals including Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital, and Ipswich Hospital can now engage with genome sequencing programmes previously inaccessible to them. Dr Jeffrey Rubasingham, clinical oncology consultant at King’s Lynn, emphasises the significant influence: “This removes the need for 80C below zero sample preservation and specialised transport, and opens the door to cutting-edge trial therapies when conventional therapies have been exhausted.” The removal of these practical limitations is set to enhance diagnostic accuracy to thousands of additional patients annually.

The Ambient Temperature Solution

The groundbreaking conservation method, pioneered at Addenbrooke’s Hospital, uses a stabilising chemical solution that safeguards genetic material from deterioration without needing deep freezing. Rather than freezing samples at 80 degrees below zero, biological samples are submerged in this solution, which halts the progressive degradation of biological information whilst allowing safe transportation at ambient room temperature. This sophisticated advancement negates the necessity of high-cost preservation apparatus and expert delivery providers, significantly lowering both expense and intricacy. The compound preserves sample integrity throughout transport, confirming that biological specimens gets to analysis centres in optimal condition for testing, independent of journey length or duration.

• Preserves DNA samples using chemical stabilisation rather than cryogenic freezing
• Permits secure specimen delivery at ambient temperature across healthcare facilities
• Removes need for costly freezing apparatus and specialised logistics
• Protects DNA integrity throughout prolonged transport times to testing centres

Nationwide Expansion and Recognition

The positive results of the room temperature preservation approach in the East of England has prompted careful evaluation of a national implementation across NHS trusts. Senior clinicians and NHS leadership recognise the transformative potential of this innovation to democratise access to Whole Genome Sequencing across the country. The technique’s simplicity and cost-effectiveness have garnered significant support from cancer experts, who regard it as vital infrastructure for current cancer treatment. First reports from participating hospitals has been extremely encouraging, with clinical teams documenting smooth incorporation into current processes and markedly enhanced treatment results. This positive trajectory suggests that in the years ahead, genomic testing could become standard practice rather than a benefit available only to people living close to major testing centres.

Recognition of this breakthrough extends beyond the NHS, with worldwide cancer research institutions endorsing its significance for global healthcare systems. The innovation addresses a core issue that has persistently limited diagnostic accuracy in isolated and under-resourced areas. Patient advocacy groups have championed the development, highlighting how technological barriers have historically generated postcode disparities in cancer services. Laraine Chung’s case illustrates the transformative effect: her ability to undergo testing at Addenbrooke’s preserved not only her vision but also prevented unwarranted surgical intervention. As the technique becomes more widely adopted, health service leaders increasingly view investment in preservation technology as essential infrastructure, similar to supporting diagnostic apparatus.

Environmental and Clinical Impact

The transition away from ultra-cold freezing technology carries considerable ecological gains alongside medical benefits. Ultra-low freezers functioning at minus 80 degrees Celsius use considerable electrical power continuously, adding significantly to hospital carbon footprints. By removing this need, the ambient temperature storage method lowers energy usage and corresponding environmental impacts across NHS organisations taking part. Simultaneously, the lowering of bespoke transport provision and ultra-cold logistics reduces fuel usage and logistics-related pollution. These ecological benefits enhance the therapeutic outcomes, illustrating how healthcare innovation can at the same time enhance patient care and environmental goals, aligning cancer services with NHS net-zero commitments.

What This Signifies for Cancer Patients

For cancer patients throughout East of England hospitals, the implementation of room temperature preservation signifies a meaningful change in availability of potentially life-saving diagnostics. Previously, patients at smaller hospital sites faced a locational barrier: their tissue samples broke down during transfer to centralised testing laboratories, rendering them unsuitable for WGS analysis. Now, with samples maintained in preserving solution, patients at Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital can access the same advanced genetic testing as those receiving care at major research centres. This expansion directly tackles what many refer to as postcode lottery healthcare, where clinical outcomes relied heavily on location rather than clinical need.

The practical implications extend beyond mere convenience. Faster, more reliable availability of WGS allows oncologists to determine exactly which cancers patients have and which treatment options will prove most effective. For some patients, this accelerates diagnosis by days or weeks—vital period when cancer is advancing. Additionally, patients may qualify for advanced research trials offering experimental treatments not accessible via standard NHS pathways. Laraine Chung’s experience demonstrates the human dimension: her test results not only preserved her vision but spared her from unnecessarily complex surgery and its prolonged recuperation period. As the technique rolls out further, thousands more patients should experience similar advantages.